FDA Adds Contrast Agent Label Warning

Cheryl Clark, for HealthLeaders Media , September 13, 2010

The FDA advised providers to record the specific GBCA and the dosage given to each patient.

 

 

 

  • Do not exceed recommended dose and prior to re-administration, allow sufficient time for elimination from body, respecting half life.
  • For patients who are receiving hemodialysis, consider promptly initiating hemodialysis following GBCA administration.
  • Present patients with a list of symptoms.
  • Report adverse events with GBCAs to Fed's MedWatch program.
  •  

     

     


    Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.
    Twitter

    Comments are moderated. Please be patient.


    MOST POPULAR

    SPONSORED REPORTS
    SPONSORED HEADLINES

    SIGN UP

    FREE e-Newsletters Join the Council Subscribe to HL magazine

    SPONSORSHIP & ADVERTISING

    100 Winners Circle Suite 300
    Brentwood, TN 37027

    800-727-5257

    About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
    © HealthLeaders Media 2014 a division of BLR All rights reserved.